Delivery Order GS35F095CA-75F40126F80130

The Food and Drug Administration issued a delivery order to International Business Machines Corporation on September 10, 2025, with a ceiling value of $1,126,329.48 under the GSA Multiple Award Schedule (MAS) to provide a centralized hub for information, resources, training, and analytical support assisting CDER reviewers in using OCS tools and services. Place of performance is Takoma Park, MD. The order is firm fixed price with an ultimate completion date of September 16, 2026. The...

<p>The Food and Drug Administration issued a delivery order to E-Paga, Inc., a minority-owned small business, on September 6, 2023, with a ceiling value of $733,635.34 for bringing a nonprescription drug to market.</p> <p>The order is issued under the General Services Administration's Multiple Award Schedule (MAS). Place of performance is Rockville, MD. The period of performance extends through November 21, 2027. Pricing is time and materials. No set-aside applies to this delivery order.</p>

<p>The Food and Drug Administration issued a $87,791 delivery order to Information Management Services, Inc. on August 6, 2025, under the GSA Multiple Award Schedule for omics data statistical services.</p> <p>The order has a firm fixed price and ultimate completion date of August 10, 2030, covering a base period plus four option years. Place of performance is Silver Spring, MD. The ceiling value is $87,791.</p>

<p>The Food and Drug Administration issued a $581,541 delivery order to Executive Information Systems, L.L.C. on July 2, 2026, under the GSA Multiple Award Schedule for FDA Analytics Modernization Agreement SAS services continuation.</p> <p>Place of performance is Westlake, MD. The order has a firm fixed price structure with an ultimate completion date of July 1, 2028. No set-aside was used for this delivery order.</p>

The Food and Drug Administration issued a delivery order to Agisol LLC, an 8(a)-certified small business, on June 8, 2023, under the GSA Multiple Award Schedule (MAS) to streamline processes and enhance functions for new drug review at the FDA's Center for Drug Evaluation and Research. The order carries a ceiling value of $4,060,216.66 and is priced on a time-and-materials basis. Place of performance is Silver Spring, Maryland, with an ultimate completion date of July 31, 2028. In fiscal year...

<p>The Food and Drug Administration issued a delivery order to Carahsoft Technology Corp on August 22, 2023, for GoAnywhere and File Catalyst software licenses under the GSA Multiple Award Schedule (MAS). The order's ceiling value is $1,345,435.44 on a firm fixed price basis.</p> <p>This is an option year 3 exercise covering the period September 1, 2026, through August 31, 2027. Place of performance is Reston, VA.</p>

<p>The Food and Drug Administration issued a delivery order to Brand Consulting Group, Inc. on July 2, 2024, under the GSA Multiple Award Schedule (MAS) for ISO audit support services to the Center for Devices and Radiological Health (CDRH) quality management system. The order carries a ceiling value of $9,971.52 and is priced on a labor-hours basis.</p> <p>Place of performance is Silver Spring, Maryland. The order was fully terminated on February 19, 2025.</p>

<p>The Food and Drug Administration awarded a purchase order to American Chemical Society for a CAS BioFinder Discovery Platform software license valued at $17,992.80, effective September 1, 2026. Place of performance is Columbus, Ohio. The order is firm fixed price with an ultimate completion date of August 31, 2027. No set-aside applies.</p>

<p>The Food and Drug Administration issued a purchase order to the National Academy of Sciences on September 18, 2024, valued at $100,000.00, for FDA support to the NASEM Leadership Consortium. The order is firm fixed price with no set-aside designation. Performance takes place in Washington, DC 20418. Ultimate completion is scheduled for September 29, 2025.</p>

This firm-fixed price purchase order contract was awarded by the Department of Health and Human Services Food and Drug Administration (FDA) to Certara UK LIMITED, doing business as Certara, a for-profit limited liability company. The $164,400 contract provides annual licenses and maintenance support for Certara's SIMCYP physiologically-based pharmacokinetic modeling software. The software is used by the FDA's Office of Clinical Pharmacology to review submissions from pharmaceutical sponsors,...